RecruitingPhase 1NCT07224074

Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)

Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-EFFECTS)


Sponsor

Johns Hopkins University

Enrollment

20 participants

Start Date

Dec 18, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Ketones are molecules generated by the body during the metabolism of fat. Exogenous ketones (EK) are substances that can raise the level of ketones in the circulation without changing diet. In this research study, the investigators are testing the tolerability, sleep effects, and dose effects of a commercially available EK product called Ketone-IQ. The investigators will administer Ketone-IQ open-label to healthy volunteers (n=20, 10 men, 10 women) before sleep in the participant's home setting and collect information about subjective sleep and GI symptoms, as well as objective data about beta-hydroxybutyrate (BHB) levels and sleep architecture using a headband-EEG device (Sleep Profiler). Participants will measure capillary BHB levels before ingestion and at 1, 3, and 5 hours post-ingestion, as well as upon awakening. Questionnaires will be used to gather feedback on the palatability of EK, GI side effects, and sleep quality. Higher scores indicate better sleep quality. Two doses (20 g and 40 g) of Ketone-IQ will be tested each for two nights, with one night used to measure BHB levels and a separate night to allow for uninterrupted sleep.


Eligibility

Min Age: 18 YearsMax Age: 50 Years

Inclusion Criteria1

  • Adults aged 18-50 years old with a BMI of 18 - 30 kg/m\^2

Exclusion Criteria9

  • No concomitant sleep disorder (e.g. sleep apnea, insomnia, restless leg syndrome, narcolepsy, idiopathic hypersomnia). If there is no known diagnosis of sleep apnea, a STOP-BANG score of 5 or higher is an exclusion.
  • No current daytime respiratory impairment such as uncontrolled asthma, or uncontrolled Chronic Obstructive Pulmonary Disease (COPD), pneumonia, interstitial lung disease.
  • No known history of chronic renal disease or diabetes (type 1 or type 2).
  • No use of supplemental oxygen.
  • Cannot be on a low carbohydrate (\<130 g carbohydrate/day) or ketogenic diet, intermittent fasting, or consuming exogenous ketones
  • Cannot be pregnancy or breastfeeding
  • Cannot be on medications: acetazolamide or Sodium-glucose cotransporter-2 (SGLT2) inhibitor (10), daily opioid use.
  • K-BREATHE: no history of claustrophobia or panic disorder
  • Frequent alcohol intake (more than 1 drink per day on average, or \> 10 drinks per week).

Interventions

DIETARY_SUPPLEMENTKETONE-IQ 20 grams (g)

Dietary Supplement: Ketone-IQ (1,3 Butanediol) Description: Ketone-IQ (1,3 Butanediol) 20g will be ingested (open-label) before bedtime.

DIETARY_SUPPLEMENTKETONE-IQ 40 grams (g)

Dietary Supplement: Ketone-IQ (1,3 Butanediol) Description: Ketone-IQ (1,3 Butanediol) 40g will be ingested (open-label) before bedtime.


Locations(1)

Johns Hopkins Bayview

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07224074


Related Trials